Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.

Breast Cancer Res Treat · 2016 · PMC4869778 · PMID 27120467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Compared to the 1.7–2.1-fold differences typically reported in overall survival between ER + /LumA versus TNBC/basal-like BC [ 8 , 9 ], these results suggest that the HR0–3 classification reveals BC sub-groups with highly significant outcome differences.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.